Class Action Filed Against Atara Biotherapeutics by Pomerantz Law Firm

Class Action Lawsuit Filed Against Atara Biotherapeutics

Pomerantz LLP, a prominent law firm specializing in securities class actions, has recently announced the initiation of a class action lawsuit against Atara Biotherapeutics, Inc. (NASDAQ: ATRA), alongside several of its executives. This legal step has been taken on behalf of all individuals and entities that purchased or acquired Atara securities between May 20, 2024, and January 9, 2026. The case, registered in the United States District Court for the Central District of California, is aimed at seeking reparations for damages allegedly inflicted due to the defendants' breaches of federal securities laws.

Background

Atara Biotherapeutics focuses on developing innovative therapies for patients suffering from various oncological and autoimmune diseases. Key among its product candidates is tabelecleucel, referred to as tab-cel or EBVALLO, which is designed to treat EBV-positive post-transplant lymphoproliferative disease (EBV+ PTLD).

The company has established a partnership with Pierre Fabre Médicament for the commercialization of tabelecleucel, relying heavily on milestone payments to fund its operations. This financial framework is significant for Atara, particularly as it aims for the regulatory approval of its drug. In May 2024, the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tabelecleucel, claiming to have sufficient data from its Phase 3 ALLELE study to back its application.

Allegations Against Atara

The complaint filed by Pomerantz LLP alleges that the defendants made multiple materially false and misleading statements about Atara's business operations and prospects. Specifically, they are accused of failing to disclose critical manufacturing issues and deficiencies in the ALLELE study that raised doubts about the FDA's approval chances for the tabelecleucel BLA.

These alleged oversights led to significant risks concerning regulatory scrutiny and threatened ongoing clinical trials. The lawsuit contends that the public statements made by the defendants were misleading and that they painted an overly optimistic picture of Atara's business health, misguiding investors throughout the class period.

The revelations began surfacing on January 16, 2025, when Atara issued a press release announcing its receipt of a Complete Response Letter (CRL) from the FDA. This letter indicated concerns stemming from a standard pre-license facility inspection, which ultimately led to a steep decline in Atara’s stock price, falling over 40% on the announcement. Further developments escalated when, on January 21, 2025, Atara disclosed that the FDA had placed a clinical hold on its active IND applications citing unresolved Good Manufacturing Practice (GMP) compliance issues.

In response to these events, Atara’s stock saw another significant drop, marking a tumultuous period for the company. The situation deteriorated further on January 12, 2026, when Atara announced another CRL regarding the resubmission of the tabelecleucel BLA, which ultimately triggered a staggering 56.99% fall in share price that day.

The Way Forward

Investors who acquired Atara’s securities during the highlighted period have until May 22, 2026, to request the Court to appoint them as Lead Plaintiff for the class action. The legal team at Pomerantz LLP is prepared to guide individuals through the process of joining this lawsuit. Interested parties can find a copy of the complaint and additional information on the firm's website.

Pomerantz LLP has built a reputation over its 85 years of operation, especially in the realms of corporate and securities litigation. The firm has a long history of advocating for the justice of investors wronged by misconduct and believes that this case emphasizes the importance of accurate disclosures in the financial market.

Conclusion

As the lawsuit unfolds, the implications for Atara Biotherapeutics and its investors remain to be seen. The case serves as a reminder of the stringent regulatory environment surrounding clinical advancements in biotechnology and the vital necessity for transparency by public companies. For more information, individuals can reach out to Pomerantz LLP.